MEG
LGND icon

Millstone Evans Group’s Ligand Pharmaceuticals LGND Stock Holding History

Millstone Evans Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42K Hold
133
– – 0.02% 377
2026
Q1 		$26.6K Hold
133
– – 0.02% 446
2025
Q4 		$25.1K Hold
133
– – 0.01% 440
2025
Q3 		$23.6K Hold
133
– – 0.02% 434
2025
Q2 		$15.1K Hold
133
– – 0.01% 478
2025
Q1 		$14K Hold
133
– – 0.01% 486
2024
Q4 		$14.3K Buy
+133
New +$15K 0.01% 459

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millstone Evans Group's LGND Position: Q2 2026 in Review

Millstone Evans Group held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 133 shares worth $42K. The position accounts for 0.02% of the portfolio, ranked #377.

Millstone Evans Group first reported a position in LGND in Q4 2024 and has held it in 7 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Millstone Evans Group held 133 shares of Ligand Pharmaceuticals worth $42K as of Q2 2026.
  • Millstone Evans Group left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up 0.02% of Millstone Evans Group's portfolio in Q2 2026, its #377 holding.
  • Millstone Evans Group first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.